Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy - Wikidata - wikimedia - TriplyDB

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

http://www.wikidata.org/entity/Q33409285

about

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.von Willebrand factor is a cofactor in complement regulation.Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.Reincarnation of ancient links between coagulation and complement.Extracellular vesicles in renal disease.Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli-Infected Mice.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases.The role of von Willebrand factor in thrombotic microangiopathy.C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles.Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.

P2860

Q26992169-41F6041E-1289-4F25-ACE4-4D42F1234984 Q33419414-E2A9A41C-A452-4590-B1DA-9B0AB7D8DF4A Q33421861-7CC29C33-52A4-4E56-ABA9-747BD6E44960 Q33427651-0C990CA3-AA21-45CB-8940-2085A70C7C33 Q33429667-21E703FC-B0BF-44C5-AE68-E10B060B0385 Q33443111-D422A312-B3E5-449F-A06F-9FE1C9422042 Q35056291-4E662160-5DCB-4162-8FD6-CC6A4A718153 Q36264512-007BDF55-7316-47DF-B946-525276602441 Q38543278-354F2127-E9A1-404F-B3FC-CA1EA58ADB2E Q39453434-027EBE2F-72C6-4A2E-872F-3C1C90E76B18 Q40612027-0F5C04DC-C15A-4CC3-A95A-11D535243C9D Q42086661-38EB1867-647C-4E69-9E69-ADB158199C09 Q47599879-F569C8A7-AA41-4FDC-801E-05B3DACF1542 Q48220242-4F03413A-FFF5-41E9-8FF2-6CF035B8D434 Q48225900-9F94485D-2EC3-4F04-8A8D-B8EEE78B1DE4 Q48338971-8F506701-71C5-4A81-9BC0-B8D84BA1D916 Q51100129-CA8011A2-B12F-414B-8370-223A4E6BC4AE Q52759733-0FC4690C-7BC2-40F8-9E28-2583107FD6E6 Q53819914-19ECE442-A3F6-4429-8673-665086716E73

P2860

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

http://www.wikidata.org/entity/Q33409285

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Complement activation associat ...... ine thrombotic microangiopathy

@ast

Complement activation associat ...... ine thrombotic microangiopathy

@en

type

label

Complement activation associat ...... ine thrombotic microangiopathy

@ast

Complement activation associat ...... ine thrombotic microangiopathy

@en

prefLabel

Complement activation associat ...... ine thrombotic microangiopathy

@ast

Complement activation associat ...... ine thrombotic microangiopathy

@en

P1433

Q33409285-1F04B18B-EDE5-4797-B810-143E972754BD

P1476

Q33409285-4126CE8E-E48C-48A5-BBC7-7A3E9FDAABBC

P2093

Q33409285-3F955168-3357-47B4-9226-F4A3FC51964A

Q33409285-58CCA31E-95FB-4DEF-9B83-A907CEF97A9A

Q33409285-7ECA0715-136E-42A1-BFE1-C433DD284E40

Q33409285-8A36364C-2BCE-413F-B3B2-DA6FBE7E2E1A

Q33409285-A3343517-ABA3-4FC1-ADD0-6A0D92315ECD

Q33409285-FC9E9077-79C0-4D5B-A58B-88479CC3F12D

P2860

Q33409285-005A5858-9C47-4582-846A-5CB7016A0449

Q33409285-01A93D84-DC97-4197-990A-C65EF324794D

Q33409285-057B285B-7B95-4B34-9639-D56E8E35AE56

Q33409285-08622B98-AB3C-484E-97E7-5A8809B8C646

Q33409285-0B3744EC-3963-42FF-83AD-12BB548C6A92

Q33409285-0B6BB362-DFDB-4CFB-B1D6-B26B76D6C214

Q33409285-0EEB751D-EA68-4A82-BB01-D8396A6036EA

Q33409285-10C56F12-8637-4FB7-834F-5001165DB4CF

Q33409285-1EBBB981-17FF-4361-9DF2-9C6E6937C851

Q33409285-20EC0B7C-B218-4A09-AE31-1EFE7B60D67D

P304

Q33409285-55149D25-8FF3-4DD8-8DE1-36AB29F9A22E

P31

Q33409285-3159F2BA-F0D1-4DC3-97B9-7CEDD193FCEF

P356

Q33409285-44CF2096-F8D8-40D8-A9FE-76FDAFE3C294

P407

Q33409285-70627B84-B1BD-4101-829A-F56ED47FF671

P433

Q33409285-B1BFF200-ED9B-43E8-B447-F75BA1E0F1A8

P478

Q33409285-0040C8FE-9827-4065-9733-A8FD66FBDC47

P50

Q33409285-864D6C7C-7DBC-419C-82C3-43F031C9B400

Q33409285-CC9757AC-8232-4DF5-8602-09480803244D

P577

Q33409285-06A8970D-65F0-4AC9-A7D1-6B78DA173611

P5875

Q33409285-A91549C1-1D59-452D-86BC-277FD636B7A6

P698

Q33409285-A4CF4423-83D6-46F4-B3C6-6AA023B1AE2E

P932

Q33409285-B9849CBF-FA1B-4EAF-9578-84A2624B68CD

P356

JIMMUNOL.1301221

P1433

Journal of Immunology

P1476

Complement activation associat ...... ine thrombotic microangiopathy

@en

P2093

Ann-Charlotte Kristoffersson

http://www.w3.org/2001/XMLSchema#string

Anne-Lie Ståhl

http://www.w3.org/2001/XMLSchema#string

Christoph Licht

http://www.w3.org/2001/XMLSchema#string

David Motto

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Ramesh Tati

http://www.w3.org/2001/XMLSchema#string

P2860

Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopeni

Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.

P304

2184-2193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1301221

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

251235872

http://www.w3.org/2001/XMLSchema#string

P698

23878316

http://www.w3.org/2001/XMLSchema#string

P932

3750088

http://www.w3.org/2001/XMLSchema#string